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Abstract
Background: Myocardial ischemia is a major cause of death in chronic kidney disease (CKD) patients, which can be
caused by either epicardial or microvascular coronary artery disease (CAD). Although renal transplantation improves
survival, cardiovascular disease remains a major cause of mortality in post renal transplant recipients, including those with
no significant epicardial CAD pre-transplant. We aim to utilize stress cardiovascular magnetic resonance (CMR) and MR
coronary angiography (MRCA) to assess silent myocardial ischemia and epicardial CAD in renal transplant recipients.
Methods: Forty-five subjects: twenty renal transplant (RT) with no known CAD, fifteen liver transplant (LT) controls
without prior CKD and no known CAD, and ten hypertensive (HT) controls underwent stress perfusion CMR and MRCA.
Results: A total of 1308 myocardial segments (576 of RT, 468 of LT, and 264 of HT) were compared using mixed linear
modeling. Left ventricular mass index, septal diameter and presence of diabetes mellitus were similar between the
groups. The mean transmural MPRI was significantly lower in the RT and LT groups compared to HT controls (1.19 ± 0.50
in RT versus 1.23 ± 0.36 in LT versus 2.04 ± 0.32 in HT controls, p < 0.0001), in the subepicardium (1.33 ± 0.57 in RT versus
1.30 ± 0.33 in LT versus 2.01 ± 0.30 in HT controls, p < 0.001), and in the subendocardium (1.19 ± 0.54 in RT versus 1.11 ±
0.31 in LT versus 1.85 ± 0.34 in HT controls, p < 0.0001). Seven (35 %) RT and five (33 %) LT had significant epicardial CAD
compared to none in HT controls, p = 0.12. One RT and one LT had LGE suggesting sub-endocardial infarction.
Conclusions: RT recipients have impaired myocardial perfusion independent of LVH or diabetes mellitus. The impaired
myocardial perfusion in RT is similar to LT without prior renal disease, thus unlikely related to previous CKD. It is not fully
explained by the presence of significant epicardial CAD, and therefore most likely represents microvascular CAD.
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Background
Cardiovascular disease is the leading cause of mortality
and morbidity in the chronic kidney disease (CKD) popu-
lation, accounting for 50 % of all deaths [1]. CKD patients
have a 10 to 20 fold increased risk of cardiac death than
the normal population, although the mechanism is uncer-
tain [1]. Furthermore, despite the risk of cardiovascular
mortality being significantly reduced by renal transplant-
ation [2], cardiovascular disease remains a major cause of
mortality in post-renal transplant recipients with an annual
event rate of 3.5 to 5 % [3]. Renal transplant recipients carry
a multitude of risk factors including traditional atheroscler-
otic (dyslipidemia, hypertension, diabetes), myocardial
(hypertension and fluid overload pre transplant), micro-
vascular (diabetes, renal failure), and immunosuppression.
Current diagnostic investigations of myocardial ischemia
in renal population lack sensitivity and specificity or may
have adverse effects [4]. Multi-parametric Cardiovascular
Magnetic Resonance (CMR) enables concurrent assessment
* Correspondence: Joseph.Selva@health.sa.gov.au
1Department of Cardiovascular Medicine, Flinders Medical Centre, Bedford
Park, Adelaide, SA 5042, Australia
3School of Medicine, Flinders University, Bedford Park, Adelaide, SA, Australia
Full list of author information is available at the end of the article
© 2015 Parnham et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Parnham et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:56 
DOI 10.1186/s12968-015-0166-5
of myocardial function, perfusion and irreversible injury
with high spatial resolution [5]. In particular, stress perfu-
sion CMR has high sensitivity and negative predictive value
for detecting myocardial ischemia with a sensitivity of 89 %
and a specificity of 80 % [6]. In addition, two large pro-
spective controlled trials,-CE-MARC and MR-IMPACT II-
demonstrated higher diagnostic accuracy of stress perfusion
CMR compared to SPECT [7, 8]. Huber et al. found that
semi-quantitative evaluation provides identical diagnostic
performance for coronary artery disease (CAD) to quantita-
tive evaluation if both stress and rest examinations were
used [9]. Recently, magnetic resonance coronary angiog-
raphy (MRCA) has emerged as an imaging alternative for
coronary artery anatomy, especially for the proximal and
mid coronary segments [10]. Finally, CMR allows accurate
quantification of ventricular function and mass as well as
tissue characterization, thereby uniquely positioning it as a
powerful modality to explore the high cardiovascular event
rate in renal transplant patients.
We sought to investigate the mechanism of cardiovas-
cular morbidity and mortality in otherwise well post
renal transplant recipients using multi-parametric CMR.
Our primary aim was to assess the presence and degree
of myocardial ischemia utilizing stress perfusion CMR
and the presence of significant epicardial disease using
non-contrast whole-heart MRCA. Majority (50–90 %) of
renal transplant recipients have hypertension [11] and
the high (75 %) prevalence of left ventricular hyper-
trophy (LVH) in CKD population [12] likely persists post
transplantation [13]. In contrast to the advanced CKD
pre-renal transplant population, the prevalence of CAD
in the end-stage liver disease patients is similar or only
slightly greater than the normal population, ranging
from 2.5 % to 27 %, however, cardiovascular disease is a
major cause of mortality post liver transplantation [14].
We used 2 control groups- an aged matched population
of hypertensive controls (to control for LVH commonly
seen in the renal transplant recipients) and a post-liver
transplant group (to allow differentiation of transplant
milieu effects from prior renal failure effects).
Methods
Study population
Renal transplant (RT) recipients who were well and with
stable renal function between three months and five years
post transplantation were invited to participate to have
CMR imaging at Flinders Medical Centre, a tertiary teach-
ing hospital in South Australia, in 2012–2014. RT subjects
had the following inclusion criteria: no established CAD
(no history of myocardial infarction, angina, coronary artery
stent or bypass surgery or angiographically documented
significant CAD> 70 %, and no significant inducible myo-
cardial ischemia pre-transplant), and no previous systolic
heart failure. Liver transplant (LT) recipients with the same
inclusion criteria were recruited. Ten people with a clinical
diagnosis of hypertension (HT) and who were asymptom-
atic with no known CAD were prospectively recruited from
the hospital’s Hypertension Clinic.
Exclusion criteria for each group were severe claustro-
phobia, metallic implants, contraindications to adenosine
(second or third degree atrioventricular block, obstructive
pulmonary disease, dipyridamole use), and contraindica-
tions to gadolinium chelate (anaphylaxis, estimated glom-
erular filtration rate (eGFR) < 45 ml/min/1.73 m2).
We identified a total of 171 RT patients from the
hospital’s renal database within the calendar year 2012.
Exclusions were: >60 months post renal transplantation
(102), ischaemic heart disease or known coronary artery
disease (11), CMR contraindication (20), <3 months post
renal transplantation (2), declined participation (13), lan-
guage barrier (2) and pregnancy (1). Following exclusion,
a total of 20 RT patients were enrolled into the study.
All participants gave written informed consent, and
the study was approved by Southern Adelaide Clinical
Human Research Ethics Committee (SAC HREC).
CMR protocol
All participants were instructed to refrain from caffeine
24 h prior to the scan. Subjects on beta blockers contin-
ued with their medications.
Cine imaging was acquired using standard method
[15]. Stress imaging with adenosine infusion 140 μg/kg/
min for 3–4 min was performed of the basal, mid, and
apical myocardial segments, using an ECG-gated T1-
weighted fast gradient echo sequence (echo time, 1.04 ms;
repetition time, 2 ms; voxel size, 29×2.3×8 mm, flip angle
17°), and a peripheral bolus injection of a gadolinium-
based agent (0.1 mmol/kg; gadolinium-based contrast
agent, Gadovist, Bayer, Australia), followed by a 15 ml
bolus of normal saline (rate 5 ml/s), as previously de-
scribed [16, 17]. All slices were imaged during each heart
beat, for a total of 50 heart beats. Blood pressure and
heart rate were recorded by an automated recording ma-
chine at baseline and at 1 min intervals during adenosine
infusion. After discontinuing adenosine for 15 min, the
same sequence was repeated without intravenous ad-
enosine to obtain resting perfusion images. For late
enhancement imaging, an additional bolus of Gadovist
(0.05 mmol/kg) was injected, and after 6 min, images
were acquired in the 3 long axes and in the short
axis plane to obtain coverage of the entire left ven-
tricle using a gated T1-weighted segmented inversion
recovery turbo fast low-angle shot sequence (echo time,
4.8 ms; voxel size, 1.4×2.4×8 mm; flip angle, 20°). The
inversion time was adjusted to achieve optimal nulling of
non-infarcted myocardium, as previously described [18].
MRCA images were obtained as a separate scan by
using an 18-channel flex coil 1.5 T clinical MR scanner
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(Siemens Sonata, Erlangen, Germany). A four-lead ECG
was obtained for cardiac gating. Glyceryl trinitrate 400
micrograms/metered dose was administered prior to
MRCA. The navigator-gated, free-breathing, non-contrast
whole-heart CMRA was acquired using a 3D segmented
Steady-State Free Precession sequence protocol as pre-
viously described [19, 20].
CMR image analysis
CMR analysis was performed with CMR42 Version 4.1,
Circle Cardiovascular Imaging Inc. Left ventricular mass,
left and right ventricular volumes and functions were
calculated using 3D short axis stack by tracing of the
endocardial and epicardial contours in end-diastole and
end-systole, as previously described [15]. Each parameter
was indexed to body surface area (BSA). The septal and
lateral wall diameters were measured in end-diastole at
mid-ventricular level from short-axis view.
For perfusion analysis, semi-quantitative analysis using
CMR42 software was used. Transmural, subepicardial
and subendocardial contours were traced and manually
corrected for breathing displacement (Fig. 1). Each basal,
mid and apical myocardial slice were divided into 6
segments with the right ventricular insertion as the
reference point [21]. Since basal myocardial blood flow
is closely related to the rate-pressure product (RPP),
and index of left ventricular oxygen consumption,
values for rest flow in each patient were also corrected
for rate-pressure product [22]: Corrected Rest perfu-
sion = (Rest perfusion/RPP) × 104. Myocardial Perfusion
Reserve Index (MPRI) was calculated as the ratio of per-
fusion during adenosine-induced hyperemia to perfusion
at rest corrected for RPP [23].
For late enhancement analysis, areas of subendocardial
hyperenhancement were assessed visually as present or
absent. The fibrosis was quantified using CMR42 soft-
ware as a percentage of myocardial mass [24, 25].
MRCA images were transferred to a 4D viewer image re-
construction CMR42 software. Three-dimensional volume-
rendered images were generated by the software. The
left main, left anterior descending artery (LAD), left
circumflex (LCx) and right coronary artery (RCA) were
manually traced and followed for their course in axial, cor-
onal, sagittal, cranial left anterior oblique, lateral, caudal
right anterior oblique and caudal left anterior oblique
views. The coronary arteries were analysed and segmented
Fig. 1 Example of Subendocardial and Subepicardial Segmentation. Rest and stress perfusion images of a transplant recipient showing inferior
and anterolateral perfusion defect (white arrows). Basal, mid, and apical short axis slices were acquired (a mid short axis slice was shown as
representative). Transmural, subepicardial (bottom) and subendocardial (top) contours were traced. The left ventricular myocardium was
segmented into six segments (anterior, anterolateral, inferolateral, inferior, inferoseptal, anteroseptal) with right ventricular insertion point as a
reference. Segmental myocardial-time intensity curves at stress (shown on the right) and at rest were measured by the CMR42 software
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according to the American College of Cardiology/
American Heart Association classification [26].
One CMR experienced cardiologist (JBS) blinded to
the clinical information and stress perfusion results,
evaluated the left main, LAD, LCx and RCA arteries
using sliding thin-slab maximum intensity projection.
Significant coronary artery stenoses were defined as lu-
minal narrowing greater than 50 % [20]. Minor coronary
artery disease was defined as luminal narrowing of less
than 50 %. The coronary artery was classified normal if
it was smooth without any plaque occupying lumen.
Statistical analysis
Statistical analysis was performed with STATA version
13.0. Parametric data is expressed as mean ± SD and
non-parametric values as median (inter-quartile range).
Independent t-tests and ANOVA was used to compare
the clinical characteristics of the study groups. Fisher’s
exact test was used for comparison of categorical vari-
ables. MPRI evaluation of coronary artery level data was
analysed using linear mixed modeling (LMM) with a ran-
dom intercept used for each subject to account for the
within-subject correlation present from measuring at 3
different artery sites. Both unadjusted and adjusted LMM
was performed with adjustment for medication use (where
significant in univariate analysis) and left ventricular mass
a priori. Statistical tests were 2-tailed and a p value <0.05
was considered statistically significant.
Results
Subject characteristics
Forty-five subjects participated in the study: twenty RT,
fifteen LT controls, and ten HT controls participated
in the study. Clinical characteristics are presented in
Table 1. Using Bonferroni correction for multiple group
comparison, the eGFR was lower in the renal transplant
group compared to hypertensive control (p = 0.012), but
similar compared to liver transplant group (p = 0.67).
The eGFR was similar between the liver transplant and
hypertensive control groups (p = 0.21). The presence of
hypertension was similar between the renal transplant and
hypertensive groups. The liver transplant group had less
degree of hypertension compared to the hypertensive group
(p = 0.027). The presence of hypertension in the renal
transplant and liver transplant groups was not statistically
different (p = 0.06). The use of statin between the renal
transplant and hypertensive groups was similar (p = 0.95).
The etiology of renal diseases in the RT group were: poly-
cystic kidney disease (n = 7), glomerulonephritis (n = 9),
diabetic nephropathy (n = 1), medication related (n = 1),
reflux nephropathy (n = 1), Alport’s syndrome (n = 1), and
unknown (n = 1). The etiology of liver diseases in the LT
group were: alcoholic liver disease (n = 7), hepatitis C
(n = 5, 1 of which was combined hepatitis C and B),
primary sclerosing cholangitis (n = 1), non-alcoholic steato-
hepatitis (n = 1), and unknown (n = 1). The mean post-
transplant duration between the RT and LT groups were
similar (33 ± 17 versus 36 ± 18 months, p = 0.44). The
immunosuppressant medications received by the RT and
LT groups are outlined in Table 2. Their exposures were
similar apart from LT patients only receiving prednisolone
in the first three months post transplantation and the use
of mycophenolate, which was more prevalent in RT
patients.
Assessment of left ventricular mass, volumes and function
The CMR results are summarized in Table 3. Left
ventricular mass index, septal and lateral wall diameter
were similar between the groups.
Assessment of Myocardial Perfusion Reserve Index (MPRI)
A total of 1308 out of 1452 (90 %) myocardial segments
were analyzable. A total of 576 of RT, 468 of LT, and 264
of HT) were analyzed and compared using mixed linear
modeling.
Figures 2, 3 and 4 show the distribution of the MPRI
across the three groups and within each of the three
coronary artery sites. Across all 3 artery sites combined,
the mean transmural MPRI was significantly reduced in
RT subjects compared to HT controls but was similar
between RT and LT subjects (1.19 ± 0.50 in RT versus
1.23 ± 0.36 in LT versus 2.04 ± 0.32 in HT controls,
p < 0.0001). The subepicardial MPRI was 1.33 ± 0.57 in
RT versus 1.30 ± 0.33 in LT versus 2.01 ± 0.30 in HT con-
trols, p < 0.001. The subendocardial MPRI was 1.19 ±
0.54 in RT versus 1.11 ± 0.31 in LT versus 1.85 ± 0.34 in
HT controls, p < 0.0001. In the renal transplant and liver
transplant subgroups, the transmural MPRI was 0.97 ±
0.54 in those with significant CAD >50 % versus 1.05 ±
0.00 in those without, p = 0.02. Fifteen out of 20 (75 %)
RT versus eleven out of 15 (73 %) LT versus one out of
10 (10 %) HT had transmural MPRI < 1.5 in at least one
coronary artery territory, p < 0.0001.
Results remained similar in mixed model regression
analysis after adjustment for statin use, aspirin use and
left ventricular mass index with MPRI lower in RT sub-
jects compared to HT controls (β = 0.85, p < 0.0001) but
similar to LT subjects (β = 0.04, p = 0.79).
Significantly, in the RT group, the mean MPRI was
associated with eGFR (β = 0.014, 95 % CI = 0.0023 to
0.026, p = 0.0019).
Assessment of myocardial fibrosis
One RT subject had late gadolinium enhancement in-
dicating sub-endocardial infarction in the inferoseptal
wall (1.7 g of infarct mass (0.8 % of LV mass)), while one
LT subject had late gadolinium enhancement indicating
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sub-endocardial infarction in the lateral wall (2.9 g of
infarct mass (2.1 % of LV mass)).
Assessment of epicardial coronary artery disease
Seven out of 20 (35 %) RT, five out of 15 (33 %) LT, and
0 out of 10 (0 %) HT controls had coronary artery
stenosis >50 % in at least one coronary artery territory,
p = 0.12. There was no significant relationship between
epicardial CAD and transmural MPRI as per coronary
artery territories (β = −0.14, 95 % CI −0.30 to 0.23,
p = 0.09). Figure 5 shows representative MRCA images
of the transplant recipients.
Discussion
Stress perfusion CMR and MRCA provide valuable
insight into the cardiac phenotype. To our knowledge,
this is the first study to investigate myocardial perfusion
in asymptomatic post renal transplantation patients using
stress perfusion CMR and MRCA. We have demon-
strated that myocardial perfusion is significantly reduced
in asymptomatic post renal transplant patients independ-
ently of the degree of left ventricular hypertrophy and
diabetes mellitus. Furthermore, MRCA abnormalities do
not seem to explain the perfusion abnormalities. Our
findings suggest that myocardial perfusion abnormalities
in renal transplant patients are predominantly due to cor-
onary microvascular dysfunction possibly secondary to
post-transplant milieu rather than significant epicardial
disease. Our study findings may assist in understanding








Age, years (mean ± SD) 55 ± 11 61 ± 6 55 ± 11 0.17
Male sex, n (%) 11 (55) 12 (80) 5 (50) 0.18
BMIa, kg/m2 (mean ± SD) 29 ± 5 30 ± 4 33 ± 3 0.26
eGFRb, mL/min/1.73 m2 (mean ± SD) 78 ± 19 89 ± 29 108 ± 30 0.009
Systolic Blood Pressure (mmHg) 131 ± 19 130 ± 14 140 ± 11 0.26
Diastolic Blood Pressure (mmHg) 77 ± 14 80 ± 9 80 ± 11 0.74
Heart Rate (beats per minute) 71 ± 11 64 ± 9 77 ± 15 0.02
Cardiovascular Risk Factors, n (%)
Hypertension 18 (90) 9 (60) 10 (100) 0.03
Diabetes Mellitus 3 (15) 4 (27) 2 (20) 0.62
Total cholesterol (mmol/L) 4.8 ± 1.2 4.5 ± 1.1 5.7 ± 1.0 0.06
Low-density lipoprotein (mmol/L) 2.1 ± 1.1 2.6 ± 1.0 3.6 ± 0.9 0.005
Triglyceride (mmol/L) 2.3 ± 1.4 1.5 ± 0.6 1.5 ± 0.7 0.08
Smoking History 7 (35) 6 (40) 3 (30) 1.00
Cardiac Medications, n (%)
Aspirin 1 (5) 0 (0) 2 (20) 0.14
Beta blocker 9 (45) 3 (20) 2 (20) 0.29
ACEc inhibitor 5 (25) 1 (7) 2 (20) 0.41
Angiotensin Receptor Blocker 3 (15) 1 (7) 5 (50) 0.07
Calcium channel blocker 5 (25) 5 (33) 5 (50) 0.54
Statin 7 (35) 0 (0) 2 (20) 0.03
Data are presented as n (%) or mean ± SD
*Assessed using ANOVA or Fisher’s exact as appropriate
aBMI indicates body mass index
beGFR, estimated Glomerular Filtration Rate
cACE, angiotensin-converting enzyme
Table 2 Prescribed immunosuppressant medications in the renal
and liver transplant groups
Renal transplant
subjects (n = 20)
Liver transplant
subjects (n = 15)
p-value*
Immunosuppressant, n (%)
Azathioprine 2 (10) 4 (27) 0.37
Mycophenolate 16 (80) 4 (27) 0.002
Prednisolone 18 (90) 0 (0) <0.0001
Cyclosporine 1 (45) 1 (7) 0.68
Tacrolimus 16 (80) 14 (93) 0.37
Everolimus 1 (5) 0 (0) 0.57
Sirolimus 1 (5) 0 (0) 0.57
*Asessed using Fisher’s exact
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the contributors to cardiac mortality and morbidity in
the post- renal transplant population, thus, may lead to
better management of coronary microvascular disease in
this population.
CMR stress perfusion has been well validated in the
assessment of epicardial coronary disease and/or cor-
onary microvascular dysfunction. A recent meta-analysis
showed stress perfusion CMR to have a high sensitivity of
89 % and a specificity of 80 % for diagnosis of significant
obstructive coronary artery disease [6]. The sensitivity
and specificity of stress CMR performed with a semi-
quantitative measure of myocardial perfusion reserve
index (MPRI) with a cutoff value of 1.5 for the detection
of functionally significant (by Fractional Flow Reserve)
coronary heart disease were 91 % and 94 %, respectively,
with positive and negative predictive values of 91 % and
94 % [27]. Impaired coronary flow reserve suggestive of
microvascular dysfunction has been reported in pre-








LVa Mass index, g/m2 64 ± 13 65 ± 11 60 ± 10 0.60
LV Septal Wall thickness, cm 1.2 ± 0.3 1.2 ± 0.2 1.1 ± 0.3 0.22
LV Lateral Wall thickness, cm 0.9 ± 0.3 0.9 ± 0.2 0.9 ± 0.2 0.81
LV End Diastolic Volume index, ml/m2 68 ± 12 62 ± 13 70 ± 13 0.43
LV End Systolic Volume index, ml/m2 18 ± 8 19 ± 8 22 ± 9 0.75
LV Stroke Volume index, ml/m2 50 ± 12 45 ± 9 46 ± 10 0.26
LV Ejection Fraction, % 74 ± 9 71 ± 8 69 ± 8 0.45
RVb End Diastolic Volume index, ml/m2 70 ± 11 67 ± 14 71 ± 18 0.73
RV End Systolic Volume index, ml/m2 27 ± 8 24 ± 6 26 ± 9 0.47
RV Stroke Volume index, ml/m2 43 ± 8 41 ± 11 46 ± 12 0.77
RV Ejection Fraction, % 62 ± 10 63 ± 7 63 ± 6 0.92
All data are presented as mean ± SD
*Assessed using ANOVA
aLV indicates Left Ventricle
bRV, Right Ventricle
Fig. 2 Mean Myocardial Perfusion Reserve Index (MPRI) of the Renal
Transplant, Liver Transplant, and Hypertensive Controls (1.19 ± 0.50 in
RT versus 1.23 ± 0.36 in LT versus 2.04 ± 0.32 in HT controls, p < 0.0001)
Fig. 3 Myocardial Perfusion Reserve Index (MPRI) of the Renal
Transplant, Liver Transplant, and Hypertensive Controls within each
of the three coronary artery territories LAD indicates Left Anterior
Descending; LCx, Left Circumflex; RCA, Right Coronary Artery
Parnham et al. Journal of Cardiovascular Magnetic Resonance  (2015) 17:56 Page 6 of 9
transplant end-stage renal disease patients without coron-
ary artery disease [28]. Impaired coronary flow reserve,
similarly, has been observed in post renal transplant pa-
tients, even at a young age [29–31]. Given the association
between LVH and reduced MPRI [32], it was important
that we controlled for the degree of LVH when assessing
myocardial perfusion in the renal cohort. Our HT, RT
and LT groups were well matched in respect of degree
of LVH, LV mass, and diabetes mellitus. Hence, our
finding of reduced MPRI in the RT group is unlikely
to solely reflect LVH or the degree of diabetes, and
likely reflects additional abnormalities in coronary micro-
vascular function and/or asymptomatic (‘occult’) epicar-
dial coronary artery disease.
In order to further identify the mechanisms of MPRI
reduction we compared the RT group with a second
control group of liver transplant patients. Pre-renal
transplant CKD patients have high prevalence of cardio-
vascular disease, in contrast, pre-liver transplant chronic
liver disease (CLD) patients have low prevalence of car-
diovascular disease [33]. Whilst most CKD patients have
hypertension, CLD patients have portal hypertension,
which causes vasodilatation and decreased in arterial
blood pressure. An et al. studied 1045 liver cirrhosis
patients matched with 6283 controls and showed that
asymptomatic cirrhotic patients had similar prevalence
of obstructive CAD compared to controls with healthy
livers [33]. However, cardiovascular disease is one of the
leading cause of death in post liver transplant patients
[34]. A retrospective study of 455 liver transplant recip-
ients by Fussner et al. showed that cardiovascular
disease developed in 10.6 %, 20.7 % and 30.3 % of liver
transplant recipients within one, five and eight years
respectively [35]. In our study, the LT and RT groups
were well matched in terms of the time post-transplant,
age, and duration and importantly exposure to im-
munosuppressive medications (except for corticoste-
roids and mycophenolate). Intriguingly, we found that
myocardial perfusion reserve was reduced in asymp-
tomatic post renal transplant patients similar to post
liver transplant patients, despite the relatively low
prevalence of CAD in chronic liver disease compared
to CKD patients, and despite early discontinuation of
steroid use in the latter. This finding tends to absolve
corticosteroid exposure as responsible for the myo-
cardial perfusion abnormality. In our renal transplant
cohort 75 % had an MPRI < 1.5 in any coronary artery
territory versus 73 % of the liver transplant cohort.
Although our numbers are small, there is a strong
Fig. 4 Subepicardial and Subendocardial Myocardial Perfusion
Reserve Index (MPRI) of the Renal Transplant, Liver Transplant, and
Hypertensive Controls (Subepicardial MPRI 1.33 ± 0.57 in RT versus
1.30 ± 0.33 in LT versus 2.01 ± 0.30 in HT controls, p < 0.001;
Subendocardial MPRI 1.19 ± 0.54 in RT versus 1.11 ± 0.31 in LT
versus 1.85 ± 0.34 in HT controls, p < 0.0001)
Fig. 5 Reformatted whole-heart magnetic resonance angiography (MRCA) with navigator-gated 3D Steady-State Free Precession sequence in
(a) transplant recipient with normal coronary arteries, (b) transplant recipient with minor coronary artery disease <50 % with irregularities (arrows),
and (c) transplant recipient with coronary artery disease >50 % stenosis in RCA (arrows)
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biologic plausibility to this finding, given the well rec-
ognized effect of immunosuppressants in potentiating
an increased prevalence of traditional cardiovascular
risk factors in this population. Tacrolimus may cause
vasoconstriction of the afferent and efferent glomerular
arterioles, similar to cyclosporine [36]. The same mech-
anism may also induce coronary vasoconstriction or
“spasm”.
In order to investigate the presence of asymptomatic
epicardial CAD, we further assessed both the RT and LT
groups with MRCA. This showed that 31 % of patients
post transplant (both liver and renal) had significant cor-
onary artery disease in at least one territory. We do not
routinely perform invasive coronary angiography before
renal or liver transplantation in our centre. Thirty-one
out of thirty-five renal transplant recipients had negative
stress imaging pre-transplantation. The remaining four
transplant recipients had inconclusive stress imaging
and underwent coronary angiography greater than five
years previously that showed only minor coronary artery
disease (less than 50 % in major epicardial vessel). There
was no significant difference between the presence of
significant CAD between RT and LT patients. Further-
more, there was no significant relationship between the
presence of significant epicardial coronary artery disease
and impaired myocardial perfusion reserve, implying
that the mechanism of MPRI reduction is small vessel
related (“coronary microvascular”) rather than epicar-
dial disease. Microvascular CAD has been shown to be
associated with reduced survival, although the rate of
survival is better than for epicardial CAD [37].
Our study has several limitations. Firstly, the sample
size for each group of patients was relatively small, con-
sistent with being a pilot study. Secondly, the MRCA
has lower diagnostic accuracy in the distal vessels com-
pared with CT coronary angiography but is a safer
option for post transplant recipients who have increased
risk of malignancy even with small dose of radiation.
Thirdly, a semi-quantitative method was used to analyze
myocardial perfusion reserve since we do not have quan-
titative method in our center. Quantitative perfusion
using CMR [17] would have permitted distinction be-
tween impaired MPRI from reduced stress myocardial
blood flow (MBF) versus increased resting MBF in post
transplant population. Non-contrast T1 mapping was
also not available at the time of the study. Our study
demonstrates the utility of multi-parametric CMR in
renal transplant recipients, and confirmation in larger
scale studies is warranted.
Conclusion
Asymptomatic renal transplant recipients have a global
reduction in myocardial perfusion, independent of the
degree of LVH and the presence of diabetes mellitus.
Myocardial perfusion is also impaired in liver transplant
recipients, thus unlikely due to previous CKD. In our
transplant cohort, the impaired myocardial perfusion is
incompletely accounted for by epicardial coronary artery
disease suggesting a pathophysiologic role for coronary
microvascular dysfunction in this clinical setting.
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